Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

The health care industry has dramatically increased its federal lobbying under President Trump, and it has paid off for those companies.

Why it matters: The influence economy has only gotten bigger over the past three years, despite Trump's calls to "drain the swamp." Lobbying expenses have soared, and in the process, the health care industry has largely gotten what it wanted in Washington.

Axios analyzed the federal lobbying reports of 60 health care companies and trade organizations from 2014 through 2019 — the last three years of the Obama administration, and the first three years of Trump's.

  • These 60 entities are among the largest trade groups and companies based on revenue.

What we found: The 60 groups in this analysis spent a collective $309 million on federal lobbying in 2019,

  • Lobbying among these 60 groups soared 10% in 2017. Spending then grew more slowly in 2018, before jumping another 9% this past year.
  • The pharmaceutical industry — and specifically its main trade group, PhRMA — have spent the most money by far on lobbying under Trump, as both he and Democrats have called out the industry's pricing tactics.
  • STAT has a more granular look at drug companies' lobbying.

How it works: The lobbying apparatus isn't just about fending off proposals that threaten health care's lucrative system.

  • Lobbyists also have helped score new industry victories under Trump, like the tax law that immediately boosted profits for many health care companies, or the year-end package that repealed a handful of ACA taxes.

Between the lines: The $309 million these groups spent lobbying last year is, for them, a bargain.

  • There's a lot these figures don't cover, including dues to trade associations and state-level lobbying.
  • But take Pfizer, the single biggest spender among health care companies. Even if you tripled its $11 million total to account for those other expenses, you'd end up at a mere 0.06% of Pfizer's $52 billion of expected 2019 revenue — or roughly four months of U.S. Lipitor sales.

These figures also don't reflect campaign contributions — another very important source of leverage, especially for drugmakers.

Go deeper: See the entire analysis

Go deeper

Scoop: Stephanie Murphy announcing challenge to Marco Rubio

Rep. Stephanie Murphy. Photo: Tom Williams/CQ-Roll Call, Inc via Getty Images

Democratic Rep. Stephanie Murphy is planning to announce a campaign for the U.S. Senate in Florida against Republican Sen. Marco Rubio in early June, people familiar with the matter tell Axios.

Why it matters: Murphy is a proven fundraiser. Jumping in now would give her an early start to build her case for the Democratic nomination and potentially force Rubio and allied GOP groups to spend heavily to retain a seat in a state that’s trending Republican.

38 mins ago - Politics & Policy

Inside the GOP's infrastructure strategy

Sen. Roger Wicker. Photo: Stefani Reynolds/Bloomberg via Getty Images

Top Republican senators are hoping the White House will make some sort of counteroffer to their infrastructure proposal when they meet with President Biden on Thursday, lawmakers and their aides tell Axios.

Why it matters: This is a sign of how serious the negotiations are, they say. In advance of the meeting, some of the senators are already publicly signaling the areas in which they have flexibility.

41 mins ago - Politics & Policy

By the numbers: Senate seats to watch in 2022

Data: Axios Research, Dave Leip's Atlas of U.S. Elections; Chart: Andrew Witherspoon/Axios

While Republicans are giddy about their chances for regaining the House next year, GOP prospects for taking the Senate remain more uncertain, data reviewed by Axios suggests.

By the numbers: At least five Republican senators are retiring after the midterms, and four of their seats are in battleground states. That makes a simple Republican-for-Republican election exchange all the more difficult.